

Nick Powell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8727793/publications.pdf>

Version: 2024-02-01

40
papers

2,495
citations

304368

22
h-index

315357

38
g-index

43
all docs

43
docs citations

43
times ranked

4280
citing authors

#	ARTICLE	IF	CITATIONS
1	The Transcription Factor T-bet Regulates Intestinal Inflammation Mediated by Interleukin-7 Receptor+ Innate Lymphoid Cells. <i>Immunity</i> , 2012, 37, 674-684.	6.6	305
2	The mucosal immune system: master regulator of bidirectional gut-brain communications. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 143-159.	8.2	256
3	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. <i>Gut</i> , 2021, 70, 1884-1893.	6.1	233
4	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. <i>Gut</i> , 2020, 69, 984-990.	6.1	232
5	Developing in vitro expanded CD45RA ⁺ regulatory T cells as an adoptive cell therapy for Crohn's disease. <i>Gut</i> , 2016, 65, 584-594.	6.1	163
6	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. <i>Gut</i> , 2021, 70, 865-875.	6.1	153
7	SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 218-224.	3.7	111
8	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 342-352.	3.7	100
9	Human retinoic acid-regulated CD161 ⁺ regulatory T cells support wound repair in intestinal mucosa. <i>Nature Immunology</i> , 2018, 19, 1403-1414.	7.0	86
10	Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells. <i>Gut</i> , 2020, 69, 578-590.	6.1	84
11	Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 222-234.	8.2	82
12	Interrogating host immunity to predict treatment response in inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 9-20.	8.2	76
13	The unusual suspects-innate lymphoid cells as novel therapeutic targets in IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 271-283.	8.2	75
14	Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal Inflammation. <i>Gastroenterology</i> , 2015, 149, 456-467.e15.	0.6	71
15	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. <i>Nature Communications</i> , 2022, 13, 1379.	5.8	48
16	Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors. <i>Rheumatology</i> , 2019, 58, vii17-vii28.	0.9	39
17	Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 389-397.	0.6	39
18	Group 3 ILCs: Peacekeepers or Troublemakers? What's Your Gut Telling You?!. <i>Frontiers in Immunology</i> , 2019, 10, 676.	2.2	34

#	ARTICLE	IF	CITATIONS
19	British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 679-697.	3.7	33
20	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. <i>Gut</i> , 2020, 69, gutjnl-2020-321927.	6.1	28
21	Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1432-1452.	1.9	28
22	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 271-281.	3.7	23
23	Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 26-48.	1.9	23
24	The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2022, 162, 1525-1542.	0.6	23
25	Advances in mesenchymal stromal cell therapy in the management of Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 141-153.	1.4	20
26	Cognitive Impairment in Adult Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Journal of the Academy of Consultation-Liaison Psychiatry</i> , 2021, 62, 387-403.	0.2	18
27	Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. , 2021, 9, e002742.		16
28	T-Bet Controls Cellularity of Intestinal Group 3 Innate Lymphoid Cells. <i>Frontiers in Immunology</i> , 2020, 11, 623324.	2.2	15
29	Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 987-988.	3.7	12
30	Topical beclometasone dipropionate in the management of immune checkpoint inhibitor-induced microscopic colitis. <i>BMJ Case Reports</i> , 2019, 12, e226481.	0.2	9
31	Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. <i>Clinical and Experimental Gastroenterology</i> , 2017, Volume 10, 57-66.	1.0	8
32	SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 528-529.	3.7	5
33	Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity. <i>Gut</i> , 2023, 72, 410-412.	6.1	5
34	Characterizing Innate Lymphoid Cell Phenotype and Function in Human Inflammatory Bowel Disease. <i>Methods in Molecular Biology</i> , 2020, 2121, 199-211.	0.4	4
35	Out of Sight, Out of Mind: The Limitations of the Hospital Anxiety and Depression Scale in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e100-e100.	0.9	3
36	Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation?. <i>Gut</i> , 2020, 69, 609-610.	6.1	3

#	ARTICLE	IF	CITATIONS
37	PTU-009...Upper gastrointestinal inflammation in patients with immune-checkpoint inhibitor induced diarrhoea. , 2018, , .		2
38	SARS-CoV-2 vaccination for patients with inflammatory bowel disease " Authors' reply. The Lancet Gastroenterology and Hepatology, 2021, 6, 523-524.	3.7	2
39	A population of naive-like CD4 ⁺ T cells stably polarized to the T _H 1 lineage. European Journal of Immunology, 2022, 52, 566-581.	1.6	2
40	Tu1244 - Effectiveness of Anti-Inflammatory Therapy in Immune Checkpoint Inhibitor-Induced Diarrhoea/Colitis. Gastroenterology, 2018, 154, S-913.	0.6	1